<DOC>
	<DOCNO>NCT01902082</DOCNO>
	<brief_summary>Currently , proven effective pharmacologic treatment available patient acute respiratory distress syndrome ( ARDS ) . Mesenchymal stem cell show effective treat several inflammatory disease . The main purpose study assess safety allogeneic adipose-derived mesenchymal stem cell patient ARDS .</brief_summary>
	<brief_title>Adipose-derived Mesenchymal Stem Cells Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>1 . ARDS diagnose use Berlin definition 2 . Eligible patient least 18 year age acute onset ARDS . 3 . Bilateral opacity chest radiography 4 . No cardiac failure 5 . PaO2/FiO2 ratio &lt; 200 1 . 72 hour inclusion criterion meet 2 . Preexisting severe disease major organ 3 . Pregnancy 4 . Pulmonary hypertension 5 . Malignant diseases 6 . HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ARDS</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>Safety</keyword>
	<keyword>Cytokines</keyword>
</DOC>